Not provided
Not provided
Not provided
Not provided
Not provided
Adjustment to the sponsor's development strategy
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Evaluate the safety, pharmacokinetics and efficacy of HEC89736 in patients with Relapsed or Refractory B-cell Hematologic Malignancies
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HEC89736 treatment | Experimental | HEC89736 tablets,25 mg, 50 mg, 100 mg, 150 mg, 200 mg, QD, 28 days for each cycle |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| HEC89736 | Drug | HEC89736 tablets QD every 28 days for each cycle |
|
| Measure | Description | Time Frame |
|---|---|---|
| Dose limited toxicities evaluated with NCI-CTC AE v5.0 after the first dose | Incidence of dose limited toxicities and associated dose of HEC89736 | Dosing started until the 28th day |
| Adverse events evaluated by NCI CTCAE 5.0 | Incidence of adverse events and associated dose of HEC89736 | From the frst dose to within 30 days after the last dose |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Li Jianyong, Doctor | The First Affiliated Hospital with Nanjing Medical University | Principal Investigator |
| Song Yuqing, Doctor | Peking University Cancer Hospital & Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Beijing Cancer Hospital | Beijing | Beijing Municipality | China | |||
| Jiangsu Province Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Nanjing |
| Jiangsu |
| China |
| ID | Term |
|---|---|
| D012008 | Recurrence |
| ID | Term |
|---|---|
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided